Bambusa Therapeutics, Inc. (NasdaqGS: BBTX)
Health Care · Biotechnology · US
$15.98
-0.68% today · +6.6% 1Y
Bambusa Therapeutics, Inc. (NasdaqGS: BBTX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $814.06M and employs 26 people.
Over the last twelve months the share price has gained 6.6%, trading between 14.99 and 17.16.
Tweenvest scores Bambusa Therapeutics, Inc. across four factors: quality 42/100, value 100/100. Its strongest factor is value.
BBTX price history
Key figures
- Market cap
- $814.06M
- Revenue (TTM)
- —
- P/E
- -49.37
- EPS
- -3.96
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $17.16
- 52-week low
- $14.99
- Avg volume (3M)
- —
- Shares outstanding
- 50.94M
- Employees
- 26
- Next earnings
- —
About Bambusa Therapeutics, Inc.
Bambusa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It engages in developing a portfolio of next-generation, multi-targeting medicines designed to transform patient care across chronic immunology and inflammation diseases. The company was founded by Shan Shan Xu, Thang Ho, and Helmut Jeggle on March 14, 2024 and is headquartered in Boston, MA.
- ISIN
- US0589371030
- Founded
- 2024
- Listed since
- Oct 30, 2026
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Syndax Pharmaceuticals, Inc.NasdaqGS: SNDX | $858.87M | $9.54 | -0.52% |
| Seegene, Inc.KOSDAQ: A096530 | $841.38M | ₩24,650.00 | -1.79% |
| Shaanxi Micot Pharmaceutical Technology Co., Ltd.SEHK: 2335 | $837.23M | HK$19.80 | -3.79% |
| City Therapeutics, Inc.NasdaqGM: CTY | $827.95M | $16.64 | -4.91% |
| L&C BIO Co.,LTDKOSDAQ: A290650 | $813.06M | ₩20,150.00 | -6.06% |
| Aimed Bio Inc.KOSDAQ: A0009K0 | $802.22M | ₩16,500.00 | -9.89% |
| Rigel Pharmaceuticals, Inc.NasdaqGS: RIGL | $800.84M | $42.53 | -1.05% |
| Ironwood Pharmaceuticals, Inc.NasdaqGS: IRWD | $791.33M | $4.78 | -1.85% |